TransCode Therapeutics (RNAZ) said Wednesday it has signed a deal with certain institutional investors for a securities' sale worth roughly $8 million.
The sale, which is expected to close Friday, includes about 21.2 million common shares, series C warrants to purchase about 21.2 million common shares, and series D warrants to purchase about 21.2 million common shares.
Net proceeds will be allocated towards working capital and general corporate purposes, the company said.
Shares of TransCode Therapeutics fell more than 9% in recent trading activity.
Price: 0.34, Change: -0.04, Percent Change: -9.81
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。